A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection, Followed by a Two-dose Open-label Cohort and Three Open-label Single-dose Cohorts in Treatment Naïve Patients, Including a Multi-dose Open-label Extension at a Single Center
Sponsor: Arrowhead Pharmaceuticals
Terminated
Company decision to discontinue trial
Other terminated trials from Arrowhead Pharmaceuticals
Other Hepatitis B, Chronic trials with similar outcome
A PHASE2 clinical study on Hepatitis B, Chronic, this trial is terminated or withdrawn. The trial is conducted by Arrowhead Pharmaceuticals and has accumulated 9 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Feb 2026 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Terminated PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Jul 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arrowhead Pharmaceuticals
- ICON Clinical Research
For direct contact, visit the study record on ClinicalTrials.gov .